Alexander Fichtner1, Caner Süsal2, Britta Höcker1, Susi Rieger1, Rüdiger Waldherr3, Jens H Westhoff1, Anja Sander4, Gerhard Opelz2, Burkhard Tönshoff5. 1. Department of Pediatrics I, University Children's Hospital Heidelberg, Im Neuenheimer Feld 430, D-69120, Heidelberg, Germany. 2. Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, Germany. 3. Institute of Clinical Pathology Heidelberg, Heidelberg, Germany. 4. Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany. 5. Department of Pediatrics I, University Children's Hospital Heidelberg, Im Neuenheimer Feld 430, D-69120, Heidelberg, Germany. burkhard.toenshoff@med.uni-heidelberg.de.
Abstract
BACKGROUND: We investigated the prognostic value of overall and complement-binding donor-specific HLA antibodies (DSA) in pediatric patients undergoing clinically indicated graft biopsies and their association with graft outcome and specific histological lesions. METHODS: Sera of 62 patients at time of indication biopsy ≥1 year posttransplant were assessed for DSA and C1q-fixing DSA by single-antigen bead (SAB) technology. RESULTS: Twenty-six patients (42 %) were DSA-positive at time of indication biopsy and nine (15 %) were C1q-positive. At 4 years postbiopsy, patients with C1q-positivity had a low graft survival (11 %) compared to DSA-positive, C1q-negative patients (82 %, p = 0.001) and to DSA-negative patients (88 %, p < 0.001). The majority (89 %) of C1q-positive patients were diagnosed with active chronic antibody-mediated rejection (ABMR). C1q DSA-positivity [adjusted hazard ratio (HR) 6.35], presence of transplant glomerulopathy (HR 9.54), and estimated glomerular filtration rate (eGFR) at the time of indication biopsy (HR 0.91) were risk factors for subsequent graft loss. CONCLUSIONS: The presence of C1q-positive DSA in the context of an indication biopsy identifies a subgroup of pediatric renal transplant recipients with a markedly increased risk of subsequent graft loss. Because a fraction of DSA-positive patients escape rejection or graft dysfunction, the C1q assay increases the specificity of a positive DSA result regarding unfavorable transplant outcome.
BACKGROUND: We investigated the prognostic value of overall and complement-binding donor-specific HLA antibodies (DSA) in pediatric patients undergoing clinically indicated graft biopsies and their association with graft outcome and specific histological lesions. METHODS: Sera of 62 patients at time of indication biopsy ≥1 year posttransplant were assessed for DSA and C1q-fixing DSA by single-antigen bead (SAB) technology. RESULTS: Twenty-six patients (42 %) were DSA-positive at time of indication biopsy and nine (15 %) were C1q-positive. At 4 years postbiopsy, patients with C1q-positivity had a low graft survival (11 %) compared to DSA-positive, C1q-negative patients (82 %, p = 0.001) and to DSA-negative patients (88 %, p < 0.001). The majority (89 %) of C1q-positive patients were diagnosed with active chronic antibody-mediated rejection (ABMR). C1qDSA-positivity [adjusted hazard ratio (HR) 6.35], presence of transplant glomerulopathy (HR 9.54), and estimated glomerular filtration rate (eGFR) at the time of indication biopsy (HR 0.91) were risk factors for subsequent graft loss. CONCLUSIONS: The presence of C1q-positive DSA in the context of an indication biopsy identifies a subgroup of pediatric renal transplant recipients with a markedly increased risk of subsequent graft loss. Because a fraction of DSA-positive patients escape rejection or graft dysfunction, the C1q assay increases the specificity of a positive DSA result regarding unfavorable transplant outcome.
Authors: B Sis; M Mengel; M Haas; R B Colvin; P F Halloran; L C Racusen; K Solez; W M Baldwin; E R Bracamonte; V Broecker; F Cosio; A J Demetris; C Drachenberg; G Einecke; J Gloor; D Glotz; E Kraus; C Legendre; H Liapis; R B Mannon; B J Nankivell; V Nickeleit; J C Papadimitriou; P Randhawa; H Regele; K Renaudin; E R Rodriguez; D Seron; S Seshan; M Suthanthiran; B A Wasowska; A Zachary; A Zeevi Journal: Am J Transplant Date: 2010-01-29 Impact factor: 8.086
Authors: Caner Süsal; Daniel Wettstein; Bernd Döhler; Christian Morath; Andrea Ruhenstroth; Sabine Scherer; Thuong H Tran; Petra Gombos; Peter Schemmer; Eric Wagner; Thomas Fehr; Stela Živčić-Ćosić; Sanja Balen; Rolf Weimer; Antonij Slavcev; Claudia Bösmüller; Douglas J Norman; Martin Zeier; Gerhard Opelz Journal: Transplantation Date: 2015-09 Impact factor: 4.939
Authors: G Einecke; B Sis; J Reeve; M Mengel; P M Campbell; L G Hidalgo; B Kaplan; P F Halloran Journal: Am J Transplant Date: 2009-11 Impact factor: 8.086
Authors: Carmen Lefaucheur; Denis Viglietti; Luis G Hidalgo; Lloyd E Ratner; Serena M Bagnasco; Ibrahim Batal; Olivier Aubert; Babak J Orandi; Federico Oppenheimer; Oriol Bestard; Paolo Rigotti; Anna V Reisaeter; Nassim Kamar; Yvon Lebranchu; Jean-Paul Duong Van Huyen; Patrick Bruneval; Denis Glotz; Christophe Legendre; Jean-Philippe Empana; Xavier Jouven; Dorry L Segev; Robert A Montgomery; Adriana Zeevi; Philip F Halloran; Alexandre Loupy Journal: J Am Soc Nephrol Date: 2017-10-17 Impact factor: 10.121
Authors: Jon Jin Kim; Olivia Shaw; Chloe Martin; George Michaelides; Ramnath Balasubramaniam; Neil J Sebire; Nizam Mamode; Anthony Dorling; Robert Vaughan; Stephen D Marks Journal: Pediatr Nephrol Date: 2017-09-16 Impact factor: 3.714
Authors: Yongkang Wu; Nicole M van Besouw; Yunying Shi; Martin J Hoogduijn; Lanlan Wang; Carla C Baan Journal: Front Immunol Date: 2016-08-23 Impact factor: 7.561